Evotec has partnered Bristol-Myers Squibb to launch a $20m commercialisation programme aimed at academic institutions in Germany’s Rhine-Main-Neckar region.
Evotec, the Germany-based drug discovery company, has added academic institutions from Germany’s Rhine-Main-Neckar region to its therapeutics commercialisation initiative.
Bristol-Myers Squibb is serving as the pharmaceutical partner to the initiative.
BeLab2122 is the latest initiative that forms part of BRIDGE, a programme created by Evotec to support drug discovery and commercialisation at academic institutions across Europe and North America.
Spinouts resulting from the partnership are collectively owned by the involved parties.
BeLab2122 is mediated and supported by regional life sciences cluster BioRN. It brings together Goethe University Frankfurt, Heidelberg University, University of Tübingen, European Molecular Biology Laboratory and German Cancer Research Center (DKFZ).
Werner Lanthaler, chief executive of Evotec, said: “We are very excited about the launch of BeLab2122, a truly transformative framework that leverages first-class science from one of Europe’s leading life science cluster regions with lots of potential to generate medical progress.
“We look forward to unlocking this potential by using our ‘data-driven R&D Autobahn to Cures’ to further validate and develop these approaches to translate the promising early-stage research into the medicines of the future.”
